$32.17
0.49% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Crinetics Pharmaceuticals Inc Stock price

$32.17
-1.15 3.45% 1M
-23.45 42.16% 6M
-18.96 37.08% YTD
-15.61 32.67% 1Y
+16.26 102.20% 5Y
+7.66 31.25% 10Y
+7.66 31.25% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.16 0.49%
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Key metrics

Market capitalization $3.01b
Enterprise Value $1.74b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,288.91
P/S ratio (TTM) P/S ratio 3,965.38
P/B ratio (TTM) P/B ratio 2.40
Revenue growth (TTM) Revenue growth -61.62%
Revenue (TTM) Revenue $760.00k
EBIT (operating result TTM) EBIT $-376.73m
Free Cash Flow (TTM) Free Cash Flow $-265.32m
Cash position $1.27b
EPS (TTM) EPS $-3.52
P/E forward negative
P/S forward 603.76
EV/Sales forward 348.50
Short interest 12.41%
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.76 0.76
62% 62%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 114 114
71% 71%
15,058%
- Research and Development Expense 263 263
43% 43%
34,613%
-373 -373
51% 51%
-49,143%
- Depreciation and Amortization 3.24 3.24
151% 151%
426%
EBIT (Operating Income) EBIT -377 -377
52% 52%
-49,570%
Net Profit -328 -328
39% 39%
-43,191%

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in...
Neutral
GlobeNewsWire
21 days ago
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
Neutral
GlobeNewsWire
29 days ago
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 437
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today